Baltic Biomaterials Centre of Excellence

What Baltic Biomaterials Centre of Excellence does

Baltic Biomaterials Centre of Excellence (BBCE) is a publicly funded research consortium headquartered in Riga, Latvia, focused on advanced biomaterials for bone tissue replacement and regeneration. Established in 2019 under EU Horizon 2020 grant agreement No 857287, BBCE integrates Latvian institutional partners (RTU RBIDC, LIOS, RSU, RSU Institute of Stomatology) with strategic international partners AO Research Institute Davos (Switzerland), Friedrich-Alexander University Erlangen-Nuremberg (Germany), INPT-CIRIMAT (France), and Goethe University Frankfurt (Germany). Its research is organised across six scientific focus groups spanning calcium phosphate synthesis and composites, drug/ion/cell delivery systems, in vitro materials testing with metabolomics and lipidomics, drug delivery kinetics and stability, preclinical in vivo evaluation, and clinical evaluation with personalized 3D-printed implants for maxillofacial, periodontal, endodontic, and orthognathic surgery. The consortium operates purpose-built laboratory infrastructure including super-resolution STED microscopy, X-ray micro-CT, UHPLC and LC-MS/MS, and a multi-platform 3D bioprinting suite (BioAssemblyBot 400, Asiga PRO 4K80, Apium M220, 3DCeram C100).

BBCE does not sell commercial products; its revenue model is grant-based, with cumulative competitive research funding of €13.62 million secured by June 2025 and 138 peer-reviewed publications produced across the consortium. Services and infrastructure access are made available through individually negotiated collaborative research agreements, co-authorships, and service contracts with academic institutions, clinical university hospitals, and biomaterials industry partners. The go-to-market motion centres on academic and clinical network development via conferences (ScSB, ESB, ECerS), summer and winter schools, staff mobility exchanges under the RISEus2 twinning project, and outreach to high-school students through BIO-GO-Higher and RISEus2 programmes. Customer segments include academic research institutions, clinical healthcare providers (hospitals and surgical centres), and biomaterials/medtech industry partners seeking collaborative research, clinical validation, and infrastructure access.

BBCE addresses the burden of musculoskeletal disabilities driven by the EU's ageing population, targeting reduced implant revision rates, lower-cost personalised implants, and improved performance through advanced biocompatible materials, additive manufacturing, and drug/biomolecule delivery. It is governed by a leadership team that includes Prof. Janis Locs as BBCE project coordinator, Prof. Kristine Salma-Ancane as Director of the Institute of Biomaterials and Bioengineering (from November 2024), Prof. Dagnija Loca, and group leaders across the six scientific directions.

Name

Baltic Biomaterials Centre of Excellence

Legal name

Baltic Biomaterials Centre of Excellence

Website

https://bbcentre.eu

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Baltic Biomaterials Centre of Excellence (BBCE) is a Riga-based, EU-funded research consortium developing advanced biomaterials and 3D-printed personalised implants for bone regeneration. It serves academic researchers, clinical hospitals, and biomaterials industry partners across Latvia, Switzerland, Germany, and France.

Ownership category

akta.pro rank

Product category

Biomaterials Research

NAICS

Scientific Research and Development Services (5417)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industries

Medical & Dental 3D Printing Services (patient-specific devices, dental labs) (IMAAADAG), Medical & Dental Prototyping (Models, Guides, Pre-Op Planning) (IMAAAFAI), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Bone regeneration biomaterials
• Calcium phosphate research
• Drug delivery systems
• 3D bioprinting implants
• Preclinical biomaterial testing

Headquarters

HQ city

Riga

HQ country

Latvia

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. EU Research Grants (Primary): BBCE is primarily funded through competitive EU research funding, notably the Horizon 2020 programme (Grant Agreement No 857287, €13.62 million secured as of June 2025). Additional funding comes from Baltic Research Programme, EEA Grants, national research programmes, and ERA-NET/EuroNanoMed projects. Revenue is grant-based, not commercially generated.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

BBCE is a research consortium conducting advanced biomaterials research for bone tissue regeneration. It operates six scientific focus groups covering calcium phosphates and composites synthesis, drug/ion/cell delivery systems, in vitro material testing, drug delivery kinetics and stability, preclinical biomaterial evaluation, and clinical evaluation with personalized 3D-printed implant development. The centre provides access to specialised research infrastructure (advanced microscopy, chromatography, spectroscopy, 3D bioprinters, in vivo facilities) through collaborative research agreements and training schools.

Product overview

The Baltic Biomaterials Centre of Excellence (BBCE) is a research institution focused on advanced biomaterials development for bone tissue replacement and regeneration. Rather than a commercial product company, BBCE operates as an academic-industry collaborative center offering research infrastructure, scientific expertise, and laboratory services. BBCE's research portfolio spans six scientific focus groups covering calcium phosphates and composites, drug/ion/cell delivery systems, in vitro material testing, drug delivery kinetics and stability, preclinical biomaterial evaluation, and clinical evaluation with personalized implant development. The center provides access to specialized research infrastructure including advanced microscopy, chromatography, spectroscopy, 3D bioprinting, and in vivo testing facilities. BBCE also runs educational outreach programs including the RISEus2 project for early-stage researcher training and the BIO-GO-Higher quiz competition for high school students in STEM subjects.

Differentiator

Problem solved

Functional benefit

Products and services

• Collaborative Research Services Joint research programmes, consortium participation, staff mobility, training schools, and collaborative research projects addressing advanced biomaterials for bone tissue replacement and regeneration, delivered to academic institutions, hospitals, and biomaterials companies.
• Research Infrastructure Access Access to specialised research infrastructure including advanced bioprinters (BioAssemblyBot 400, Asiga PRO 4K80, Apium M220, 3DCeram C100 EASY LAB), super-resolution STED/FLIM/FCS microscopy, X-ray micro-computed tomography, SEM, UHPLC, LC-MS/MS, FTIR, Raman spectroscopy, and in vivo testing facilities, offered to academic, clinical, and industry partners.
• Training Schools (Summer and Winter Schools) Annual training schools covering scientific writing and presenting skills, in vivo experiments, drug/ion/cell delivery systems, calcium phosphates and composites, and materials in vitro, held at partner institutions across Europe (Davos, Frankfurt, Toulouse, Riga) for early-stage researchers.
• Clinical Evaluation and Personalized Implant Development Clinical studies on biomaterials for bone regeneration using 3D planning and printing technologies, maxillofacial surgery, periodontology, endodontics, anatomical models, surgical guides, personalized implants, facial reconstruction after trauma and tumour resection, autotransplantation of teeth, and orthognathic surgery.

Quantifiable outcome

• 138 scientific papers published by June 2025, demonstrating substantial research output
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Scandinavian Society for Biomaterials (ScSB)minorStrategic or Co-development Partner · 1 January 2022ScSB is the Scandinavian professional society for biomaterials research. BBCE co-organised and hosted the ScSB 2022 Annual Meeting in Jurmala, Latvia (101 participants from 17 countries), facilitating networking between BBCE researchers and the Scandinavian biomaterials community.
• Latvian Materials Research SocietyminorStrategic or Co-development Partner · 1 January 2022The Latvian Materials Research Society is the professional association for materials research in Latvia. Co-organised the ScSB 2022 conference alongside BBCE and Baltic Incentive Travel Ltd. BBCE director Kristīne Šalma-Ancāne serves as President of the Latvian Materials Research Society.
• Journal of Functional Biomaterials (MDPI)minorOthers · 1 January 2022Journal of Functional Biomaterials (CiteScore 7.3, Q1 in Biomedical Engineering) served as a scientific journal media partner for ScSB 2022, with abstracts published in eCM journal and a Special Issue 'Advances in Biomaterials Engineering' available to registered participants.
• Institute National Polytechnique de Toulouse CIRIMAT (INPT-CIRIMAT)coreStrategic or Co-development Partner · 1 January 2021INPT-CIRIMAT is a French research institute and RISEus2 consortium partner specialising in calcium phosphates, biomaterials synthesis, and drug delivery systems. The partnership includes joint summer/winter schools, staff mobility secondments, collaborative research on biomaterials characterisation, and co-authored publications.
• FORM-Lab Frankfurt Orofacial Regenerative Medicine, Goethe University Frankfurt (GUF)coreStrategic or Co-development Partner · 1 January 2021GUF's FORM-Lab is a key partner providing expertise in in vivo studies, clinical biomaterials research, and maxillofacial surgery. The partnership under RISEus2 includes summer schools on in vivo experiments, staff mobility visits, and collaborative translational research in head and neck regeneration.
• AO Research Institute Davos (ARI)coreStrategic or Co-development Partner · 1 January 2019ARI is a leading international research institute in musculoskeletal regeneration and serves as BBCE's primary strategic partner alongside FAU. The long-term strategic cooperation involves collaborative research, staff mobility, joint publications, and technology transfer in biomaterials for bone tissue replacement. ARI contributed to the H2020 BBCE and RISEus2 project proposals and implementation.
• Friedrich-Alexander University Erlangen-Nuremberg (FAU)coreStrategic or Co-development Partner · 1 January 2019FAU (Institute of Biomaterials) is a key strategic partner providing expertise in biomaterials science and serving as the organiser of BBCE Summer Schools on scientific writing. The partnership involves collaborative research, knowledge transfer, and joint training activities under the BBCE and RISEus2 projects.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Geistlich Biomaterials: Geistlich is a global commercial leader in dental bone regeneration products (e.g., Bio-Oss, Bio-Gide), directly competing in the bone graft substitute and dental regeneration markets that BBCE researches. It represents the type of commercial entity BBCE's research could feed through technology transfer.
• DSM Biomedical: DSM Biomedical (now part of dsm-firmenich) is a global biomaterials supplier for medical devices and tissue engineering. It serves as a commercial analogue and potential partner for BBCE's research-grade biomaterials and drug delivery systems.
• Stryker (Orthopedics & Regenerative): Stryker is a major orthopedic medical device company with regenerative medicine offerings, representing a potential downstream acquirer or development partner for BBCE's bone regeneration and personalized implant research outputs.
• Evonik Industries (Biomaterials): Evonik supplies biomaterials used in medical implants and tissue engineering, including resorbable polymers and calcium phosphate precursors. As a large specialty chemicals player, it overlaps with BBCE's drug delivery and biomaterial synthesis focus as a potential materials supplier/partner.

Direct peers

• AO Research Institute Davos (ARI): ARI is a leading international musculoskeletal regeneration research institute and BBCE's primary strategic partner. Both organizations focus on biomaterials for bone tissue replacement, share joint grant proposals (H2020 BBCE, RISEus2), and conduct parallel translational research in regenerative medicine.
• INPT-CIRIMAT (Toulouse): CIRIMAT is a French research institute specializing in calcium phosphates, biomaterials synthesis, and drug delivery. As a RISEus2 partner, it overlaps substantially with BBCE's Group 2 (Drug/Ion/Cell Delivery) and calcium phosphate research focus.
• RTU Rudolfs Cimdins Riga Biomaterials Innovations and Development Centre (RBIDC): RTU RBIDC is BBCE's host institution and primary Latvian partner, housing Groups 1-3 of the BBCE research programme. It is the originating research group from which BBCE was built and shares substantial research infrastructure, scientists, and grant administration with BBCE.
• Friedrich-Alexander University Erlangen-Nuremberg (FAU) - Institute of Biomaterials: FAU's Institute of Biomaterials is a strategic partner of BBCE contributing expertise in biomaterials science and organizing BBCE Summer Schools. Both institutions conduct calcium phosphate, bioprinting, and biomaterial characterization research with overlapping scientific focus.
• FORM-Lab, Goethe University Frankfurt (GUF): FORM-Lab specializes in orofacial regenerative medicine and clinical biomaterials research. As a RISEus2 partner providing in vivo studies and maxillofacial surgery expertise, it overlaps with BBCE's preclinical and clinical evaluation groups.

Emerging players

• BICO (formerly CELLINK): BICO/CELLINK is a leading bioconvergence/bioprinting company and a sponsor of ScSB 2022 hosted by BBCE. The companies share bioprinting technology focus and could become a commercialization partner for BBCE's 3D bioprinting research in bone tissue engineering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/bbcentre_eu
• Facebookfacebook.com/bbcentre.eu

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Baltic Biomaterials Centre of Excellence